0.00Open0.05Pre Close0 Volume1.19K Open Interest1.00Strike Price0.00Turnover132.90%IV28.84%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier28DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.1598Delta0.4892Gamma26.70Leverage Ratio-0.0021Theta-0.0002Rho-4.27Eff Leverage0.0009Vega
ALX Oncology Stock Discussion
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced tha...
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
ALX Oncology (Nasdaq: ALXO) announced that results from their Phase 1b/2 trial combining evorpacept with zanidatamab in HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. The presentation will showcase data from...
Please close above the 20
No comment yet